Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, March 28, 2024 | Back issues
Courthouse News Service Courthouse News Service

Securities Class Action

A federal judge dismissed some of the class action claims against Iovance Biotherapeutics Inc. that accused the company of misleading investors by paying writers to promote its stock, ruling the plaintiff could not trace his stock to the disputed offering.

SAN FRANCISCO - A federal judge on Thursday dismissed some of the class action claims against Iovance Biotherapeutics Inc. that accused the company of misleading investors by paying writers to promote its stock, ruling the plaintiff could not trace his stock to the disputed offering.

Categories / Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...